k novo nordisk shares hit an all-time high. the ceo tells cnbc what is next on the approval horizon. >> it's a dynamic situation now, and as we ramp up, it's a surprise. this goes nice and hand in hand, and we can grow and benefit and bring this to health care systems. >> novartis grows. the ceo highlights some of the challenges facing the business. >> we do face some products losing exclusivity. we have three products chl we expect to lose exclusivity in the u.s., so that creates a little bit of headwinds for us. >> microsoft's and alphabet's numbers fails to impress investors with google sharply lower in trades after ad revenue missed expectations. >>> and paramount soars in u.s. premarket after media entrepreneur submits a $30 million offer a month after cnbc learns warner brothers entered its own preliminary merger talks with the firm. >>> well, it's difficult to believe this, but it's already january 31st, the end of the month already. we're going to take a look back how some of the key indices performed over the month of

novo nordisk says souls will surge thanks to its obesity shot.uld grow 26% but possibly up to 29% as sales fell short of innospec to him and. the details around the earnings and how it sets up the biggest market cap in europe going into and through 2024, a group picture, what stands out? >> as you said it expects growth to continue, so that sounds positive. one concern is capacity. name invested into capacity and the company said it's going to invest six and a half-billion into expanding. they're trying to allay fears that it going to run out. these drugs are treating 40 million people. tom: ok, so demand is forecast to hold the. eli lilly has been described as breathing down the next of novo nordisk. how much of a risk is that through this year? >> a lot of companies are getting into it. how long will the patent last? it is expected to be through 2029 the company will produce the drugs without generics. those are risks alongside capacity constraints. we don't really know how the drugs will be funded, whether they will be state-funded, whether pe

novo nordisk have been scaling up supply, they've been adding more lines.u follow one number, on obesity -- the company controlled how much of that was put in the market. you need a starter dose to get on treatment. they are almost toppling supply of that. what does that tell you? tells me they are confident they can meet demand with supply. obviously, demand is far greater . what scaling up of the starter dose tells you is the company is confident the supply situation improved. katie: let's talk about eli lilly and the competitive landscape. you heard novo warn of intensifying competition and usher on the price of obesity and diabetes drugs. price war? rajesh: it's easy to say, there are two players and there will be a war. reality is if you think of intensifying competition, bigger picture is almost every other pharma company owns a share. look at the market consensus. people think obesity market is between $85 billion to $100 billion potential. others are not going to sit and watch. it was launched at a price point lower because dosing is smaller. that's

we picked four carter start us off with novo nordisk. >> of course this is the definition of god-likeu have just a steady, orderly up trend. that's the momentum. it's right as a matter of technique to stick with it does it have to continue, no probably it is arrow to the right my judgment. >> not a pair of twos. >> opposite. definition of god-like. >> pair of kings. >> yeah. >> starbucks is out on tuesday what do you see here >> talk about a real laggard, right. this is a company that over the past year is down 14% s&p, up 10 and so the issue is, last quarter, it gapped up 10%, a big successful quarter gaps come in twos or threes. bet long here that you get another very sort of happy post-earnings pop. >> exxon is out towards the end of the week here so what does the chart look like in. >> exxon not a novo nordisk, of course, but a selloff to a level of support and my thinking you play for a bounce here. >> and gm, early next week. >> yes this is a company, i mean, look has a short-term chart for a reason the same price it was 15 years ago, right it basically doesn't ever work but thi

novo nordisk soaring today after posting supersize fourth quarter results. sing 36%, boosted by the popularity of its obesity drugs. novo anticipating 2024 sales to grow by as much as 26%. joining us now to dig into the obesity boom, jared holz. great to have you with us. >> i knglad to be here. >> i don't want to say it's easy, but when there's more demand for a drug than you can make, it's pretty easy to meet expectations. >> yeah, i think that's exactly what happened. the quarter, i didn't think, was so gang buster. i thought it was good relative to expectations, slight beat. but yeah, i think the party line from novo is that demand/supply imbalance favors them by a great deal, which it seems like it does. i feel like people still want to own the stock. >> i hear that zepbound is a lot easier to get ahold of and novo is saying they're going to increase production of the lower dose. and i'm wondering what your read is, because in theory, lilly should be much more effective than novo. so, are we going to see a differentiation? when will you start thinking ma

novo nordisk also offers a savings program for their drugs, ozempic and wegovy.lly and novo nordisk to make these drugs in oral versions as well as an easy alternative to the current injectables. lynn says she could have used other options after feeling dismissed by her doctor when she tried to question her weight loss medication. >> i told my physician i had heard a lot about mounjaro. and my physician just made an offhand joke that he had somebody he knew that had taken the drug and that was the end of the conversation. >> i think a lot of people think of obesity as an issue of willpower, it's not. 40% of adult americans have excess weight or obesity. that's a big number. >> reporter: lynn, who has been overweight her entire life, eventually got her medication adjusted. she has lost 65 pounds so far. >> at the correct dosage, it shuts off the constant thought of food. i feel like a normal person for the first time. >> wow, fascinating stuff. what about cost? does this makes these drugs more affordable? >> no. without insurance these drugs are about over $1,000

even novo nordisk and apple on desk for earning ands novo nordisk and obesity drug and look what they said today, there's huge demand for that and that's $1,000 a month for people to pay for it. how do you see the consumer because i think maybe the strength maybe what is coming back. jot consumer has been resilient and defiant and defiant over the excess saving ands coming through various amount of means and from stimulus and fact that people are locked and loaded with the mortgage rates and they pay down their debt and had less debt they're paying out during the pandemic and couldn't spend the things they wanted to and that's a cushion for saving balance sheets have been stunning and there's some signs and consumer are not paying down and more credit card debt and compounding at faster rate and we see income growth is now very much in the positive and that's important and the tail wind going into the beginning of 2024 having wages and not as rapidly as inflation. real wage gains and regaining some of that purchasing power we lost due to inflation and consumers are still concerned abo

. >> novo nordisk, the maker of ozempic and wegovy, says not unexpectedly, patients experienced weight they stopped taking the medication, adding obesity is a chronic disease that requires long tum management, much like high blood pressure or high cholesterol. experts stress these drugs should be used in combination with lifestyle changes like more exercise and a better diet. one study found. when patients stopped taking the medication, the average weight gain rebound is about two thirds of the total weight previously lost. >> coming up, a big change at starbucks. plus, the 16 year old global phenomenon in the sport of darts. >> this new features in the weightwatchers app just dropped! i've lost 60 pounds and i can still enjoy all of the foods i love. small changes lead to big results. weightwatcher's new app features can make your weight loss journey easier, so all you gotta to do, is you. join weightwatchers today. my frequent heartburn had me taking antacid after antacid all day long but with prilosec otc just one pill a day blocks heartburn for a full 24 hours. for one and done hea

.>> we saw numbers out of novo nordisk that they have -- we cannot run we can do anything other thannd it's working for them. are you surprised that this medicine has so many applications, all of which should be good news for thermo fisher.>> there has been clinical trial work going on, and looking at more indications on where medicines can be helpful. when there is strong demand, it creates a reinvestment cycle in r&d and it attracts vc funding for new companies that are going after the dream of bringing out new medicines that will make a difference to society. >> one thing people may not know about you, but you are the chair of the u.s. china business counsel for the last couple of years. i will posit something. i was talking to going this morning and a bunch of businesses in commercial real estate. the two countries are really not doing that great together. but business people may be doing better together. is there any hope that china can pick up in 2024 for thermo fisher?>> so when i think about the interactions i've had with the u.s. administration and the chinese government, cl

stuart: i noticed you said novo nordisk worth $500 billion. stuart: rock well automation manufacturing slow down. lauren: down 15% and getting pmis over a career and under 50 and that's contraction and a lot of inventory and they get new words and have trouble meeting the types to deliver because of disruptions in the red sea and their first quarter profit missed estimates. stuart: phillips 66 and based obstructing cerumen iran. lauren: they're up and shares at new high and hitting high earlier and solid earnings report sustained demand for fuel and they're still around. stuart: i first game to america and california, saw phillips 66 everywhere and the circle with 66 on it. lauren: you're right. stuart: seen it for years and years and years. thank you, lauren, coming up, 21 states now considered proposals to crack down on dei on college campuses. sounds like people are getting tired of woke policies in the school. mike rowe will take that on for us. >> it's gone like full communist and out of his mind and approach to law enforcement is so insa

. >>> danish pharmaceutical giant novo nordisk reports quarter 4 results. company expects demand for the two products to continue strong in 2024. joining us now is lars fruergaard jorgensen, ceo. how much of this market are you now serving and how do you see that developing your ability to supply it in the coming year? >> thank you for having me this morning. we see a very, very large opportunity going forward, and, honestly, we're just getting going. we're serving a very small faction of the market and we're scaling the market. you see a sustained growth, but it's still a very small part of the overall market we're going to address this coming year. >> you're attempting to aggressive will i increase supplies. as for o'companies, i wonder how this race is going to go, your ability to kind of get out there and exploit the lead you have had in these products while other companies are also rushing to do so. how is that shaping up right now? >> i actually think that it's a positive that we have competition because i think the main challenge will be the opportun

busy week with nearly 20% of the s&p reporting on tuesday, we hear from microsoft and alphabet novo nordiskeports on wednesday alongside gsk. boeing numbers will be under scrutiny as well amid the fallout from safety concerns thursday is reporting from apple and meta it will be a very busy week. we will be here to bring you the latest that is it for the show. i'm silvia amaro "worldwide exchange" is coming up next. shipstation saves us so much time it makes it really easy and seamless pick an order print everything you need slap the label on ito the box and it's ready to go our cost for shipping, were cut in half just like that go to shipstation/tv and get 2 months free ah, these bills are crazy. she has no idea she's sitting on a goldmine. well she doesn't know that if she owns a life insurance policy of $100,000 or more she can sell all or part of it to coventry for cash. even a term policy. even a term policy? even a term policy! find out if you're sitting on a goldmine. call coventry direct today at the number on your screen, or visit coventrydirect.com. shopify's point of sale system h

novo nordisk is number one. they've been capacity constrained. this is a more complicated story.'re the first to do this and it's a clever move. >> a fabulous company, fabulous product. listening to what you were saying, i'm not sure this actually changes the profitability. they're cutting out the middleman. that's fine. they actually don't want to get a cut of it. i'm not sure they're making that much money on these diet drugs. i'm not taking anything away from eli lilly. at 50 times forward earnings it is priced to perfection and things can go wrong. >> what do you like better than this? >> vertex -- this is not a diet drug. cystic fibrosis is its core business and it's expanding into sickle cell anemia and pain is the killer drug coming up. it looks like it has the effects of the opioids without the addictive property that will be a blockbuster. >> all right. josh, do you have a take on this space? >> look, i think it's an area where you really can look and say there's not a lot of challenge here valuation wise. the real question, is this the year they deliver? is this the yea

it is a sector dominated by novo nordisk and eli lilly.am fazeli from bloomberg intelligence for the deep dive. how much of this is a 2023 story? what kind of momentum do we see from big pharma? >> one of the key things we have noticed now is a similar thing that you have seen in the ai stocks. they started the year not looking pretty yesterday, right. i think there might be a risk of that going on this year, too, that people played the obesity wave or idea last year and now they are looking elsewhere in health care. that might be a trading situation. because this is, as you see the estimate behind you, $80 billion is the number they will be going for, there's people who've got a bigger number in mind. it is clearly a very massive unmet need and there's many reasons to be doing this in terms of trying to treat obesity. kriti: you are seeing some of the bigger health care companies, i think pfizer, merck, starting to diversify their portfolios and everybody wants a piece of this anti-obesity, weight loss medication. what does the competitiv

and novo nordisk up a little bit, up a tenth of a percent.t's europe's most valuable company, a new record-high for the stock after they see sales grow 26% this year. it's a mixed bag when it comes to earnings, but overall the sentiment is somewhat mixed. >> joumanna bercetche in our london newsroom. >>> it will be the first time boeing opens its books since the midair alaska airlines door plug blowout this month. joining me now with more is ken herbert, aerospace and equity research analyst at rbc. you have a price target of 285, stocks trading at 200. it's your least favorite, but you seem pretty optimistic. >> yes. we're still pretty optimistic in the long term. travel continues to hold up pretty well we think the cash outlook the company previously provided probably had a little bit of pressure. we do feel that $200 share of the set junk over the longer term remains favorable. although when we published on our preview, we said the outlook is certainly more challenged and we thought there was some pressure on the stock headwinding into the

novo nordisk also offers a saving programs for their drugs ozempic and wegovy and there are on goingrugs in oral versions as well as an easier alternative to the current injectables. lynn says she could have used other options after feeling dismissed by her doctor when she tried to question her weight loss medication. >> i told my physician i had heard a lot about monojouro and my physician just made an off hand joke that he had someone he knew who had taken the drug mon your row and that was sort of the end of the conversation. >> i think a lot of people think of obesity as an issue of willpower. it's not 40% of adult americans have excess weight or obesity that's a big number. >> reporter: lynn, who has been overweight her entire life she has lost 65 pounds so far. >> at the correct dosage, it shuts off the constant thought of food. i feel like a normal person for the first time. >> yeah, this could be a huge change for a lot of people. by the way, one more key component of this direct access model is cost. right now, zepbound costs just adjusted insurance, and eli lilly says a lot

also been investigating the risk of suicidal thoughts and people taking these various medications novo nordisk, which makes several of the drug say that they're safe and effective when taken under the supervision of a doctor. >> we're going to take a break here on the kron 4 morning news. but up next, we're going to talk to parents who've lost children to suicide at the golden gate bridge. there's a project to prevent these from happening in the future and it's finally been finished. we'll take a closer look. loving this pay bump in our allowance. wonder where mom and dad got the extra money? maybe they won the lottery? maybe they inherited a fortune? maybe buried treasure? maybe it fell off a truck? maybe they heard that xfinity customers can save hundreds when they buy one unlimted line and get one free. now i can buy that electric scooter! i'm starting a private-equity fund that specializes in midcap. you do you. visit xfinitymobile.com today. >> a 29 is the time and we're looking at a gorgeous day. we are right on dry on this thursday morning, john, here with the forecast. good morning jog

mention the tip of the earnings fear, let's get a little bit deeper, starbucks, general motors, a&e, novo nordiskmastercard, merck, exxon mobil and so many more names open their books as well, with investors tightly coiled ahead of so much potential market news and pushing the dow and s&p to record highs, let's get to the floor show joining me said tara jean goldman and henriette and walsh kevin mahn. jean i will start with which one of these things we just laid out do you think is the biggest potential to move the markets even higher or lower? >> thank you for having us on your show. the big thing is fomc on wednesday it'll be huge in a sense for new voting members, boz tech, master, bargain, daily they are hawkish and will put hawkish into their meeting. the fed is not going to cut standpoint. more importantly jay powell, the press conference he is a very tight rope, inflation is rolling over and come down below the fed expectation for year end of 2.4% the economy is resilient but at the same time he's going to say were to be very data dependent he could not say we're going to cut rates sooner

by the way, speaking of price hikes, novo novo nordisk and e eli lilly both recently raised the pricespopular weight loss drugs by more than the rate of inflation. >>> investors owning united rentals at this hour. united rentals is right at the top of the s&p 500. the company posted fourth quarter revenue that beat estimates. the equipment rental company also forecasting full-year 2024 revenue that is hire than expectations. in addition, the board authorized a new $1.5 billion share repurchase program that will be finished by the first quarter of 2025. you know when they put an endpoint on it instead of just is making a promise, shareholders really like that. means they're going to follow through on it. united rentals up 12.25 right now. macy's moving higher on a new york post report that sycamore if partners is exploring a possible bid for the department store chain. so the stock is up 3.5%. sycamore has had talks under wraps with macy's since late december according to sources familiar with the situation. last week the retail chain rejected ark house management's $5.8 billion bid. we

and how the markets have seized on these an anti-obesity drugs, and if you think about lilly and novo nordisk, combined $1 trillion in market cap, we have never really see that in big pharma. do you think some of the other things that gym just jim just m do you think they have the potential to be megatrends? >> first of all, let me say that i have a fund called prime time partners and we don't invest in drugs or anything that requires fda approval, so, i'm not promoting a drug. i can personally envision my wife, before i married, just got married, my previous wife who passed away three years ago, passed away from alzheimer's after having it for 12 years and i saw that decline. if you had a cure for alzheimer's, i don't think there's any end to how big it could be. if ozempic and these other comparable drugs are producing the kind of revenues they are in a very short period of time, everybody is going to want to prevent a neurological decline, and it's not just alzheimer's, it's parkinsons and essesenilit germ. i have no way of valuing those two drug companies and i'm skeptical how soon we're

shares of novo nordisk, which manufacturing rival wegovy held onto its gains, jumping 4%, closing at a record. so, did lilly just change the game for the health care industry? how will the stocks respond? guy? >> i don't know if they changed the game. clearly, they are onto something. i think other companies will act in kind. and you saw in terms of wba, walgreens/boots alliance, which had its own issues, that was clearly under pressure. in terms of the price action we just mentioned, that's the story today. traded big volume, closed lower on the day after making a new all-time high. i want to be crystal clear. eli lilly, we've loved for years. you had opportunities to buy this stock on dips a number of times and today might be one of those days that sets up for that type of opportunity. and when i say opportunity, i'm not talking about $600, i'm talking about getting back down to $535 to $550. great company, but think about it now. now it's just north of 50 times next year's numbers, which is 2 1/2, 3 turns more than its rivals. deserved, but expensive. >> the question whether or no

next, if, hypothetically, it is no longer one that people want to go with, with say eli lilly or novo nordisk? >> sure. we have been very bullish on amgen, we've said this time and time again, and i think this is going to be a huge breakout in '24 and '25, if they have great data, with a potentially monthly or postsibly quarterly maintenance drug i think the stock would be great if that works. there's smaller companies in the space, as well, like srrk, and structure, gpcr, so, a lot there, but amgen is really the big one. >> all right, we talked about this idea of m&a in 2024 and the vast amounts of cash on the sidelines from these companies. what types of companies, if it's not glp-1, could be the target more so of bio tech m&a this coming year? >> so, i think that if you listen to all the comments last week, we had a great note out about that, you have a bunch of companies saying that, first, m metabolic, cardiovascular, you think about the cash coming in and the sales forces that everything related to that is going to be important. we talked about some of those plays. i would say that in c

have also been investigating the risk of suicidal thoughts and people taking these medications novo nordisk, which makes several of the drug says they are safe and effective when used under the supervision of a doctor. coming up next at noon. >> the push for treatment not the new proposal on the state ballot this march and that solving the mental and homeless crisis. plus, 2 men charged with murder and not guilty pleas for the deadly shooting of a security guard in oakland. details ahead. and the united farm workers labor union endorses congressman adam schiff for the u.s. senate. why they say he's the best person for the job. >> kron 4 is your local election headquarters, united farm workers. labor union is endorsing congressman adam schiff and his campaign for the u.s. senate. that's the seat once held by late senator dianne feinstein. our capitol correspondent eytan wallace has more. >> well, shift came here to the united farm workers office in salinas and a part of the state known as the salad bowl of the world where they grow produce for people across the globe. it's all part of just m

. >> and people who've been taking these medications, the company novo nordisk, which makes several ofse drugs. they say that they are safe and effective when used under the supervision of a doctor. >> coming up next on the kron, 4 morning news, we're going to talk to parents who have lost loved ones to suicide at the golden gate bridge. this after a project to prevent deaths like this. finally finished. like this. finally finished. we'll have the full story. when you smell the amazing scent of gain flings... time stops. (♪♪) and you realize you're in love... steve? with a laundry detergent. (♪♪) gain flings. seriously good scent. >> it sent 29. it's dry out there. january 4th thing of bitterness is why we live why paid big bucks to live? the weather like this in january. got on a other center. hey, john. yeah, this isn't so bad at all. we're looking at a really nice day today and tomorrow got a few be out there on the golden gate, enjoying it. and i've seen a lot more of you on the embarcadero and other spots like that. looking outside from mount tam at the bay. it's all about the sun

popular weight loss, drugs like ozempic and one jaro the price of those epic which is made by novo nordiske 3.5%. it is now almost $1000 for a month's supply. eli lilly's one jaro is up 4 and a half percent. it is also about $1000 for a month's worth of that medication. company officials say the price increases are in response to changes in the health care system. market conditions and inflation. also for your health, just 15 minutes of daily exercise could help save your life, especially if you work at a desk. researchers in taiwan found the people who sit for most of their workday face a nearly 35% greater chance of dying from heart disease. but they say engaging in 15 to 30 minutes exercise each day can reverse that risk, taking regular breaks and moving around can also bound out that risk as well as opting for a standing desk. experts say prolong sitting can impact blood flow and lead to diabetes and kidney disease, which can affect your health. we do have some developing news now out of hawaii where there are some mixed updates for the highness banyan tree. it's sitting on maui after

novo nordisk became -- half $1 billion in market value.rugmaker expects a 26% jump in revenue and 29% increase in operating profits. the ceo says the company is well-positioned to grow its patient base. >> we have access to some 50 million patients in the u.s. and we are only serving a small fraction of that. that is ample opportunity for competition, and this is about growing the market, serving more patients than it is a matter of market share. yahaira: that is your bloomberg brief. jonathan: up next, investors betting big on ai. >> ai, ai, ai. cannot say it enough. these are companies that are best in their industry, they have their financial metrics, but they are pushing up against valuations. jonathan: that conversation coming up very shortly. live from new york city this morning, good morning. equities pulling back just a touch. this is bloomberg. ♪ ♪ p back. i made that. with your very own online store. i sold that. and you can manage it all in one place. i built this. and it was easy, with a partner that puts you first. godaddy. ho

don't forget, again, novo nordisk is sort of number one.arket share against wegovy with the diet drug, which from the studies that we have seen is very, very effective. now, we also got ushback on these diet drugs because even at $550 a month, that's a lot in terms of employers covering it, so especially if it is something that someone has to be on these drugs for a lifetime, there is still a lot of employers that are trying to figure out how they can afford this. we have even seen a report this morning that more employers are more insurers are looking at bariatric surgery and make that more accessible because that's just a one-time, $25,000 or $30,000 expense rather than a lifetime of these drugs and these drugs that are new, so they're still on patent. >> bertha, things moving so fast, more news from lilly in this direct area, the company commenced legal action against some importers and distributorses they say fraudulently claiming to sell mo mounjaro or zepbound and in an open letter, it is saying it does not promote or encourage use of

pepsi or novo nordisk? james: definitely pepsi.ld. we have 70 multi national and regional competitors around the world. the drugs are something certain segments of the financial community got focused on, but when you break down the data i do not think it is a big thing for us. if you want to make it super simple, we sell a range of beverages. at the end of the day you can eat less calories. you cannot have less liquid. jonathan: let's talk about products. about 40% of americans are obese. if the gop -- if these drugs really kick on and this is the solution to a monster problem, to have to change the products? two things start to shift? james: the product mix has been shifting already. the zero calories are continuing to grow steadily over the last couple of decades. it'll be another piece of the puzzle. lisa: who is your main competitor? james: we face a range of competitor. lisa: who is the person you wake up every morning and you look and you say what is that guy doing? james: that is not how i wake up in the morning. if i just c

the biggest corporate beneficiary has been novo nordisk. >> a new contender has entered the ring. >>g and it looks to be even more effective. it is also cheaper. >> it set off a horse race to see who will take the biggest part of this enormous market. >> in 2019 they traded at comparable levels. since 2021 when the fda approved will go be, valuation soared, tracking alongside companies such as apple who are being valued on how much they are likely to grow. >> the market was $2.5 billion. we estimate it could be in excess of $80 billion by 2030. >> we have two competitors so that will make the market figure. yvonne: that is the subject of our big take story with eli lilly being late but focusing on nine. they said decades ago this was the next thing to watch but it was rejected by people within the companies who wanted to focus on diabetes. no one is going to use a needle to shoot drugs into them to lose weight. and it has really shown that they were really wrong. so the question is can they catch up? david: the way this was framed was that eli lilly was late to the game. but if they

novo nordisk, the makers of ozempic and wegovy saying not on expensively patients discover regain oncety is a chronic disease that requires long-term management like highbred though it meant blood pressure or high cholesterol. these should be used in combination with lifestyle changes like exercise and food. >> if you stop taking the medicine that's working on your weight, your weight is going to start to come back. some people can maintain the weight loss, but not everybody can. >> and the fda announcing it's looking into some possible other side effects with ozempic including hair loss and suicidal thoughts. so some real things to consider. >> a lot of research still going. thank you as always. coming up, with a parenting playbook for the new year, the experts will tackle your questions from homework to health and don't go anywhere. stick around, three times in one hour. we are warming up for "gma3". we will be right back, everybody. ♪ ♪ introducing ned's plaque psoriasis. [camera shutter sfx] he thinks his flaky, red patches are all people see. otezla is the #1 prescribed pill to tr

♪ ♪ ♪ ♪ ♪ >>> welcome back, everybody. 2024 is set to be a big year for weight loss drugs, as novo nordiskst developments for their products, including using them for more than just obesity. that could give these drugs the potential to be covered more broadly, such as by medicare. joining us right now is dr. scott gottlieb. he is former fda commissioner and a cnbc contributor. he also serves on the boards of pfizer and alumna. and dr. gottlieb, first of all, good morning, and welcome. second of all, let's talk about what these drugs -- for 2023, it was huge for these drugs. what are these new developments? what do you expect to hear? >> a lot of data will come out this year that will be important to building the thesis around these drugs. analysts expect upwards of 14 million people to be on these medicines by 2030. that's about 5% of the proposition. right now you have about less than 2% of the population on these medicines. and i think you'll see continued growth and fast growth. it's really going to turn on two trends that will start to unfold in greater magnitude this year. first, succ

novo nordisk, eli lilly claiming the drugs will pay for themselves with the cost and the health carevery single year. lisa: there's been a host of different stories. this is a real question. who bears the cost? oneness is going to be covered by insurance? how do you calculate who benefits? who will pay for dialysis and these other things associated with obesity and diabetes? these are some of the questions as we parse out is this the same macro trend is artificial intelligence? all just living in an ozempic world? you have a different kind of consumer experience. tom: i'm walking down lexington avenue. there's a sign out like they are selling m&ms or pizza. come in and get your ozempic. these little signs. jonathan: you sound like you just walked pastor local bodega. delis? lisa: sort of storefronts that have unclear kind of signs that say come in. jonathan: have they replaced the old covid testing places? lisa: covid and cbd distribution. jonathan: no stores have been empty for a long time. lisa: let's make it back to the economy. jonathan: they did say they will pay for themselves.